Yazar "Sezer, A." seçeneğine göre listele
Listeleniyor 1 - 18 / 18
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Clinical Benefit of First-Line Cemiplimab in Patients with Locally Advanced NSCLC: Subgroup Analysis from EMPOWER-Lung 1(Elsevier Science Inc, 2021) Bondarenko, I.; Sezer, A.; Kilickap, S.; Gumus, M.; Ozguroglu, M.; Gogishvili, M.; Turk, H. M.[Abstract Not Available]Öğe Clinical Benefits of First-Line (1L) Cemiplimab Monotherapy by PD-L1 Expression Levels in Patients With Advanced NSCLC(Elsevier Science Inc, 2021) Kilickap, S.; Sezer, A.; Gumus, M.; Bondarenko, I.; Ozguroglu, M.; Gogishvili, M.; Turk, H. M.[Abstract Not Available]Öğe CLINICALLY UNDETECTABLE OCCULT THYROID PAPILLARY CARCINOMA PRESENTING WITH CERVICAL LYMPH NODE METASTASIS(Editura Acad Romane, 2016) Tastekin, E.; Can, N.; Ayturk, S.; Celik, M.; Ustun, F.; Guldiken, S.; Sezer, A.Background. Occult papillary thyroid carcinoma presented as isolated cervical lymphadenopathy without clinical and radiologic findings has been rarely reported. Case report. A 47 years old female patient admitted to otorhinolaryngology clinic with 4X3 cm sized cervical mass. Physical examination of the patient was noted as a nontender, firm, mobile lymph node at right lateral cervical region. There was no inflammatory or infection disease in the history of patients anamnesis and no abnormal value on laboratory tests. Ultrasound screening of the neck detected a lymph node with suspicious features for malignancy. Head and neck examination was normal and there is no evidence of a tumoral mass or nodule in the thyroid gland. Whole body scan of MRI showed no pathologic sign both in the neck and body. Excisional biopsy was performed and revealed a carcinoma with papillary morphology. Immunohistochemical staining features of the tumor confirmed a papillary carcinoma derived from the thyroid gland. Second look USG of the neck and thyroid was performed but it revealed no tumoral mass. The patient underwent total thyroidectomy with right functional and central lymph node dissection. Histological examination of the thyroid gland showed multicentric 2 mm sized, three foci of papillary carcinoma located in bilateral thyroid lobes and metastatic lymph nodes in the right side of the neck. Conclusion. A metastatic cervical lymph node can be evidence of a clinically undetected occult papillary thyroid carcinoma. Specific immunohistochemistry staining of specimen may lead to appropriate surgery and progression of carcinoma may be hindered by application of additional RAI therapy.Öğe Effect of epidural levobupivacaine on recovery from vecuronium-induced neuromuscular block in patients undergoing lower abdominal surgery(Australian Soc Anaesthetists, 2011) Sahin, S. H.; Colak, A.; Sezer, A.; Arar, C.; Sevdi, S.; Gunday, I.; Sut, N.The aim of this study was to evaluate the effect of epidural levobupivacaine on recovery from vecuronium-induced neuromuscular block. Ninety patients undergoing lower abdominal surge, were randomised into two groups after an epidural test dose: the epidural group (n=45) received a bolus of 15 nil of 0.5% levobupivacaine whereas the control group (n=45) did not. Anaesthesia was induced and maintained with propofol, fentanyl, vecuronium and nitrous oxide. Neuromuscular block was induced with vecuronium 0.1 mg/kg and monitored with acceleromyographic train-of-four at the adductor pollicis. Patients in each group received neostigmine at 25% recovery of the first twitch of train-of-four during recovery from anaesthesia. The effect of epidural levobupivacaine on the speed of recovery of neuromuscular function was evaluated. The lag time, onset time and time from vecuronium administration until 25% T1 recovery did not differ between the groups. The times of the recovery index (the time from 25% to 75% recovery of T1) and of the DUR 25-train-of-four 90 (time from 25% T1 to train-of-four ratio of 0.9) in the epidural group were significantly longer than those for the control group (5.2 [2.1] vs 3.04 [1.02] minutes and 10.8 [3.3] vs 8.2 [2.3] minutes, P < 0.001). This study shows that epidural levobupivacaine significantly delays the train-of-four recovery from vecuronium-induced block. Although the interaction is small in the clinical setting, anaesthetists should take this interaction into consideration when combining general and epidural anaesthesia during surgery.Öğe Effectiveness of preoperative plasmapheresis in a pregnancy complicated by hyperthyroidism and anti-thyroid drug-associated angioedema(Taylor & Francis Ltd, 2013) Bilir, B. Ekiz; Atile, N. Soysal; Kirkizlar, O.; Komurcu, Y.; Akpinar, S.; Sezer, A.; Demir, M.Hyperthyroidism is not a rare entity in pregnancy and 85% of these cases attributed to Graves' disease (GD). There is no therapeutic modality for GD considered as totally safe in pregnancy. Fetal and neonatal risks of maternal hyperthyroid disease are related to the hyperthyroidism itself and/or to the medical treatment of the disease. There are no data supporting an association between congenital anomalies in the fetus and propylthiouracil (PTU). Hepatotoxicity, cytopenias - especially agranulocytosis and quite rarely, angioedema, may be seen as side effects of PTU. In this case report, we examine an instance of Graves' hyperthyroidism diagnosed during pregnancy. In this case, a serious side effect during antithyroid drug usage was encountered, eventually resulting in surgery in the second trimester. This intervention was assisted by the use of plasmapheresis to obtain rapid normalization of serum thyroid hormone levels.Öğe EMPOWER-Lung 1: Cemiplimab (CEMI) monotherapy as first-line (1L) treatment of patients ( pts) with brain metastases from advanced non-small cell lung cancer (aNSCLC) with programmed cell death-ligand 1 (PD-L1) ?50%-3-year update(Elsevier Science Inc, 2023) Kilickap, S.; Ozguroglu, M.; Sezer, A.; Gumus, M.; Bondarenko, I.; Gogishvili, M.; Turk, H. M.[Abstract Not Available]Öğe EMPOWER-Lung 1: Phase III first-line (1L) cemiplimab monotherapy vs platinum-doublet chemotherapy (chemo) in advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) ?50%(Elsevier, 2020) Sezer, A.; Kilickap, S.; Gumus, M.; Bondarenko, I.; Ozguroglu, M.; Gogishvili, M.; Turk, H. M.[Abstract Not Available]Öğe INTRAVENOUS PARACETAMOL REDUCED THE USE OF OPIOIDS AND EXTUBATION TIME AFTER MAJOR SURGERY IN INTENSIVE CARE UNIT(Springer, 2009) Memis, D.; Inal, M. T.; Kavalci, G.; Sezer, A.; Sut, N.[Abstract Not Available]Öğe INVESTIGATION OF THE RELATIONSHIP OF TNFRSF11A GENE POLYMORPHISMS WITH BREAST CANCER DEVELOPMENT AND METASTASIS RISK IN PATIENTS WITH BRCA1 OR BRCA2 PATHOGENIC VARIANTS LIVING IN THE TRAKYA REGION OF TURKEY(Macedonian Acad Sciences Arts, 2020) Ozdemir, K.; Gurkan, H.; Demir, S.; Atli, E.; Ozen, Y.; Sezer, A.; Tuncbilek, N.Modifying genes play an exclusive role in the genetic regulation of the risk of breast cancer development in women with a pathogenic variation of BRCA1 or BRCA2. Therefore, it has been suggested that TNFRSF11A, which is among those modifying genes present in breast cancer development, may have a significant role in patients with positive BRCA1 or BRCA2 variations. In our study, we investigated the probable effects of single nucleotide polymorphisms (SNPs) in the TNFRSF11A gene, such as rs4485469, rs9646629, rs34739845, rs17069904, rs 884205, rs4941129 on the risk of breast cancer in patients with BRCA1 or BRCA2 variations. A total of 23 breast cancer patients with pathogenic variations in the BRCA1 or BRCA2 genes, 28 patients with no pathogenic variations in the BRCA1 or BRCA2 genes, and 55 healthy women as a control group, were included in this study. The SNPs were determined with allelic discrimination analysis through the real-time polymerase chain reaction (qPCR) method. There was no statistically significant difference between the SNPs of the TNFRSF11A gene rs4485469, rs9646629, rs34739845, rs17069904, rs884205, rs4941129 and metastasis, estrogen receptor, progesterone receptor and CerB2 receptor positivity between patient and control group (p >0.05). However, the rs4485469 SNP was found to be borderline significant between the patient groups with and without BRCA1 or BRCA2 mutations (p = 0.059). In patients with BRCA1 or BRCA2 pathogenic variations living in the Trakya region of Turkey, we could not determine the relationship between TNFRSF11 SNPs with breast cancer risk.Öğe Is Flow Cytometry Crossmatch Analysis Using Sera with Different Dilutions Important for Pretransplant Analysis? A Case Report(Elsevier Science Inc, 2012) Sagiroglu, T.; Tozkir, H.; Kilicarslan-Ayna, T.; Yagci, M. A.; Sezer, A.; Carin, M.The most effective form of treatment for chronic renal failure is kidney transplantation from a cadaver or a living donor. For a kidney transplant to be successful, tissue compatibility and a lack of donor-specific anti-human leukocyte antigen (H LA) antibodies in the circulation of the patient are vital, in addition to ABO blood group compatibility. The presence of anti-HLA antibodies. is assayed before transplantation using various methods, but because organ rejections have been observed in previous studies, different techniques are required to detect anti-FILA antibodies. Today, flow cytometry crossmatching is one of the most important and effective techniques in testing for donor-specific anti-HLA antibodies (DSAs). If weakly positive serum is assayed after serial dilution, it can yield high positivity. Herein, we describe the differences between the results for diluted and undiluted weakly positive sera studied using the flow cytometry crossmatch (FCXM) technique. In a recent study, the sera of weakly FCXM-positive patients were diluted 1/50, and the FCXM test was repeated. The use of diluted serum eliminated the effect of the prozone so that the DSAs could be detected.Öğe Malignant gastrointestinal neuroectodermal tumour in small intestine presented with perforation in young man; a rare case(Springer, 2021) Tastekin, E.; Demirtas, E. Mercan; Oztorun, B.; Sezer, A.[Abstract Not Available]Öğe THE MANAGEMENT OF THYROTOXICOSIS BY THERAPEUTIC PLASMA EXCHANGE IN PATIENTS COMPLICATED WITH ANTITHYROID DRUGS(Editura Acad Romane, 2011) Sezer, A.; Guldiken, S.; Turgut, B.; Irfanoglu, M. E.Objective. Antithyroid drugs, surgical excision, and radiation therapy with I-131 are the common treatment modalities thyrotoxicosis. The medical treatment of thyrotoxicosis has approximately 0.35% serious complications which consist of agranulocytosis, liver necrosis and failure. Therapeutic plasma exchange is an effective preoperative preparation method in thyrotoxicosis patients who are candidates for surgery and unable to manage an euthyroid state with medical treatment. Patients and Methods. This study was constructed between 2002-2009 in 9 patients who were resistant or had complications with medical treatment of thyrotoxicosis. The therapeutic plasma exchange procedures were performed with discontinuous flow cell separator devices. Results. Seven patients were females and 2 patients were males. The mean age was 51.22 years (32-78 years). The mean duration of the disease was 35.4 months (3-120 months). The patients underwent 3.3 (2-6 sessions) session of therapeutic plasma exchange before surgery. The mean volume of plasma exchange was 10549 mL (7150-18372 mL). The plasma is exchanged with %10 albumin and/or fresh frozen plasma. The complication rate was 22% during therapeutic plasma exchange. Four patients underwent near total thyroidectomy and five patients underwent total thyroidectomy. The mortality rate was zero. Neck hematoma causing acute respiratory compromise and requiring urgent evacuation developed in one patient. Conclusions. Total plasma exchange is an effective and safe procedure in preoperative preparation of the patients with thyrotoxicosis who were resistant or complicated with antithyroid drug in which a high level of concern and steady supervision is mandatory to prevent life threatening preoperative and postoperative complications.Öğe Poorly differentiated thyroid carcinoma accompanying with follicular variant papillary thyroid carcinoma: a case report(Springer, 2021) Betul, D.; Can, N.; Puyan, F. Oz; Yalta, T. D.; Usta, I.; Bulbul, B. Y.; Sezer, A.[Abstract Not Available]Öğe THE PROTECTIVE EFFECT OF AMIFOSTINE ON RADIATION-INDUCED PROCTITIS: SYSTEMIC VERSUS TOPICAL APPLICATION(Elsevier Ireland Ltd, 2011) Uzal, M. C.; Sezer, A.; Usta, U.; Sut, N.; Ozen, A.; Yagci, M. A.[Abstract Not Available]Öğe A RARE CLINICAL PRESENTATION: A PATIENT WITH CHRONIC RENAL FAILURE, SECONDARY HYPERPARATHYROIDISM AND CALCIPHYLAXIS(Editura Acad Romane, 2016) Celik, M.; Ayturk, S.; Celik, H.; Can, N.; Kucukarda, A.; Sezer, A.; Guldiken, S.Calciphylaxis, also known as calcific uremic arteriolopathy (CUA), is usually observed in women and it is a serious complication of hyperparathyroidism secondary to chronic renal failure. CUA is characterized by ischemic tissue loss secondary to progressive vascular degeneration. Although it is rare, it may end up with sepsis and organ failure and can be fatal. Its pathogenesis is not fully understood, but it is thought that it occurs secondary to increased calcification activators such as oxidized LDL, TNF-alpha, calcitriol, fibronectin, collagen-I, and TGF-1 alpha. The most effective treatment is managing underlying pathology and decreasing serum calcium and phosphorus levels. In this report, we aimed to present an end stage renal failure case with coexisting hyperparathyroidism, hyperthyroidism and calciphylaxis in whom cutaneous manifestations were healed 6 months after parathyroidectomy.Öğe Relationship between the carotid intima-media thickness and mammographic vascular calcification(Wiley-Blackwell, 2010) Tuncbilek, N.; Guldiken, S.; Sezer, A.; Mentes, A.; Cagli, B.[Abstract Not Available]Öğe Three years survival outcome and continued cemiplimab (CEMI) beyond progression with the addition of chemotherapy (chemo) for patients (pts) with advanced non-small cell lung cancer (NSCLC): The EMPOWER-lung 1 trial(Elsevier, 2022) Ho, G. F.; Ozguroglu, M.; Kilickap, S.; Sezer, A.; Gumus, M.; Bondarenko, I.; Gogishvili, M.[Abstract Not Available]Öğe Three-year Outcomes per PD-L1 Status and Continued Cemiplimab Beyond Progression plus Chemotherapy: EMPOWER-Lung 1(Elsevier Science Inc, 2023) Garassino, M. C.; Kilickap, S.; Ozguroglu, M.; Sezer, A.; Gumus, M.; Bondarenko, I.; Gogishvili, M.[Abstract Not Available]
